Discover the differences
Therapeutics testing covers a wide range of areas from controlled substance monitoring to pharmacogenomics (PGx). Our testing delivers clarity on drug use to advance understanding and improve patient outcomes. We provide access to Mayo Clinic experts and a test menu developed through evidence-driven clinical innovation to help clinicians guide patient care.
“The goal is not to identify every drug technically possible, but to perform medically necessary testing for those drugs that are most likely to impact clinical outcomes.”
Paul Jannetto, Ph.D., Director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab
Our difference
News and updates
The latest
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.
In this “Hot Topic,” Paul Jannetto, Ph.D., highlights Mayo Clinic’s targeted benzodiazepine assay and discusses the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
Visit Mayo Clinic Laboratories at booth #2047 to learn about our comprehensive therapeutics test offerings. Developed by board-certified experts in clinical chemistry, molecular, and toxicology testing, our testing is designed to detect and monitor therapeutic and illicit drugs across several relevant specimen types.
Misdiagnosed with acromegaly, a disease marked by too much growth hormone, and plagued by a host of mysterious health problems from unnecessary medications, Kelly DuBois finally found answers after pharmacogenomic testing from Mayo Clinic Laboratories put her on a path toward healing.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.
For Billy Dowell Jr., a competitive golfer, focus, determination, and course correction are essential to excelling at the sport. These skills, along with routine follow-up care and testing, are also important to navigating a life impacted by multiple chronic autoimmune conditions.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Paul Jannetto, Ph.D., associate professor of laboratory medicine and pathology at Mayo Clinic, and discusses how CBD can affect your health, what the medical benefits are, and its impact on urine drugs of abuse testing.
Loralie Langman, Ph.D., explains the difference between chain of custody and clinical toxicology testing. Chain of custody is a process used for toxicology testing when the results might have legal implications for the individual tested. Clinical toxicology testing is used for routine medical care. Mayo Clinic Laboratories offers a full range of clinical and forensic toxicology testing.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.
Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to the most-effective treatment for each patient.
Bringing together advanced testing technology, unparalleled expertise, and a patient-focused approach, Mayo Clinic Laboratories’ new high-resolution urine drug testing profile, ADMPU, evaluates for 22 drug classes including alcohol, marijuana, and nicotine, enabling clarity on substance use and precision insights that propel treatment.
Partnering with Mayo Clinic has helped St. Clair Health improve patient care and gain a new competitive advantage in pharmacogenetics.
John Black, M.D., co-director of the Personalized Genomics Lab at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D., about mental health awareness. In this episode, Dr. Black and Dr. Pritt review key takeaways from Mental Health Awareness Month, the role that lab testing plays in mental health, and the robust science behind treatment.